LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

Search

Artivion Inc

Cerrado

SectorSanidad

28.8 -0.48

Resumen

Variación precio

24h

Actual

Mínimo

28.44

Máximo

29.06

Métricas clave

By Trading Economics

Ingresos

16M

-505K

Ventas

1.7M

99M

BPA

-0.012

Margen de beneficios

-0.51

Empleados

1,600

EBITDA

2.7M

2.1M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+12.42% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

233M

1.2B

Apertura anterior

29.28

Cierre anterior

28.8

Noticias sobre sentimiento de mercado

By Acuity

23%

77%

56 / 382 Clasificación en Healthcare

Artivion Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

14 may 2025, 23:40 UTC

Acciones populares

Stocks to Watch: UnitedHealth Group, Foot Locker, CoreWeave

14 may 2025, 23:33 UTC

Principales Movimientos del Mercado

UnitedHealth Group Shares Fall After WSJ Reports of Investigation for Possible Medicare Fraud

14 may 2025, 23:25 UTC

Principales Movimientos del Mercado

Biohaven Shares Down as FDA Extends PDUFA Data for Troriluzole

14 may 2025, 23:25 UTC

Ganancias

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth -- Update

14 may 2025, 22:58 UTC

Ganancias

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth

14 may 2025, 21:35 UTC

Ganancias

Cisco Systems Names Patterson as CFO, Patel as President

14 may 2025, 23:59 UTC

Charlas de Mercado

Implications of Xero's Cost Outlook Aren't Clear -- Market Talk

14 may 2025, 23:49 UTC

Charlas de Mercado

Xero's Cost Outlook Likely to Prompt Downgrades -- Market Talk

14 may 2025, 23:48 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

14 may 2025, 23:48 UTC

Charlas de Mercado

Nikkei May Decline on Profit-Taking After Recent Gains -- Market Talk

14 may 2025, 23:47 UTC

Charlas de Mercado

Gold Gains on Possible Technical Recovery -- Market Talk

14 may 2025, 23:34 UTC

Adquisiciones, fusiones, absorciones

Agnico-Eagle Mines to Subscribe for 30M Voting Common Shares of Foran Mining in Non-Brokered Private Placement at C$3 a Share

14 may 2025, 23:10 UTC

Ganancias

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth -- Update

14 may 2025, 23:07 UTC

Ganancias

CoreWeave Posts Strong Revenue and Wins Google as a Customer. Stock Still Dives on Outlook. -- Barrons.com

14 may 2025, 23:00 UTC

Principales Noticias

UnitedHealth Group Is Under Criminal Investigation for Possible Medicare Fraud -- WSJ

14 may 2025, 22:43 UTC

Ganancias

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth

14 may 2025, 22:34 UTC

Ganancias

Xero Expects 1H Operating Expense Ratio to Be Higher Than 2H>XRO.AU

14 may 2025, 22:33 UTC

Ganancias

Xero Expects FY26 Operating Expense Ratio of 71.5%>XRO.AU

14 may 2025, 22:30 UTC

Ganancias

Xero Did Not Declare a Dividend>XRO.AU

14 may 2025, 22:30 UTC

Ganancias

Xero FY Operating Expenses 71.8% of Operating Revenue Vs. 73.3%>XRO.AU

14 may 2025, 22:30 UTC

Ganancias

Xero FY Free Cashflow Margin 24.1% Vs. 20.0%>XRO.AU

14 may 2025, 22:30 UTC

Ganancias

Xero FY Free Cashflow NZD506.7M Vs. NZD342.1M>XRO.AU

14 may 2025, 22:28 UTC

Ganancias

Xero FY Ebitda NZD638.5M Vs. NZD497.4M>XRO.AU

14 may 2025, 22:28 UTC

Ganancias

Xero FY Adjusted Ebitda NZD640.6M Vs. NZD526.5M>XRO.AU

14 may 2025, 22:27 UTC

Ganancias

Xero FY Rev NZD2.10B Vs. NZD1.71B >XRO.AU

14 may 2025, 22:27 UTC

Ganancias

Xero FY Net NZD227.8M Vs. Net NZD174.6M >XRO.AU

14 may 2025, 22:23 UTC

Principales Noticias

Boeing, GE Aerospace Get Qatar Airways Order After Saudi AI Tech Deals -- 2nd Update

14 may 2025, 22:15 UTC

Ganancias

Correction to Cisco Earnings Article -- WSJ

14 may 2025, 21:48 UTC

Ganancias

CoreWeave Posts Strong Revenue but Stock Dives on Updated Outlook -- Barrons.com

14 may 2025, 21:37 UTC

Ganancias

Cisco Reports Solid Earnings. The Stock Is Rising. -- Barrons.com

Comparación entre iguales

Cambio de precio

Artivion Inc previsión

Precio Objetivo

By TipRanks

12.42% repunte

Estimación a 12 Meses

Media 32.5 USD  12.42%

Máximo 35 USD

Mínimo 30 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Artivion Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

4

Comprar

0

Mantener

0

Vender

Sentimiento

By Acuity

56 / 382 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Artivion Inc

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.